PANORAMIC trial

The Platform Adaptive Trial of Novel Antivirals for Early Treatment of COVID-19 in the Community (PANORAMIC Trial) is a clinical trial in the United Kingdom to test the effectiveness of new antiviral drugs at the early stages of COVID-19 infections.[1][2][3] The study aims to find out if antivirals can prevent the need for hospitalisation and help faster recovery for people aged over 50 and those at higher risk due to underlying health conditions.[4] PANORAMIC is sponsored by the University of Oxford and funded by the National Institute for Health and Care Research (NIHR).[5] The trial was launched in December 2021, and as of June 2022, over 25,000 people are enrolled as participants.[6]

  1. ^ "PANORAMIC". www.panoramictrial.org. Retrieved 16 March 2022.
  2. ^ "Thousands needed to try a new Covid antiviral treatment". BBC News. 25 January 2022. Retrieved 16 March 2022.
  3. ^ "Public urged to sign up to world-first COVID-19 antiviral study". GOV.UK. Retrieved 16 March 2022.
  4. ^ "Covid cost-cutting will put blinkers on our best Covid research". the Guardian. 21 February 2022. Retrieved 16 March 2022.
  5. ^ "NIHR funds community COVID-19 antiviral trial". www.nihr.ac.uk. Retrieved 16 March 2022.
  6. ^ Pinching, John (22 February 2022). "PANORAMIC view of World's largest COVID study". PharmaTimes. Retrieved 16 March 2022.